Minocycline ( DrugBank: Minocycline )
13 diseases
告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
2 | 筋萎縮性側索硬化症 | 2 |
6 | パーキンソン病 | 1 |
8 | ハンチントン病 | 2 |
13 | 多発性硬化症/視神経脊髄炎 | 8 |
46 | 悪性関節リウマチ | 2 |
85 | 特発性間質性肺炎 | 1 |
90 | 網膜色素変性症 | 2 |
94 | 原発性硬化性胆管炎 | 1 |
162 | 類天疱瘡(後天性表皮水疱症を含む。) | 1 |
201 | アンジェルマン症候群 | 3 |
206 | 脆弱X症候群 | 4 |
280 | 巨大動静脈奇形(頚部顔面又は四肢病変) | 1 |
299 | 嚢胞性線維症 | 3 |
2. 筋萎縮性側索硬化症
臨床試験数 : 645 / 薬物数 : 589 - (DrugBank : 163) / 標的遺伝子数 : 150 - 標的パスウェイ数 : 225
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00355576 (ClinicalTrials.gov) | July 2006 | 21/7/2006 | Combination Therapy Selection Trial in Amyotrophic Lateral Sclerosis | Phase II Combination Therapy Selection Trial in Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis | Drug: Celecoxib;Drug: Creatine;Drug: Minocycline | Columbia University | ALS Association;Pfizer | Completed | 21 Years | 85 Years | Both | 86 | Phase 2 | United States |
2 | NCT00047723 (ClinicalTrials.gov) | January 2003 | 16/10/2002 | Minocycline to Treat Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis | Drug: minocycline | National Institute of Neurological Disorders and Stroke (NINDS) | NULL | Completed | 21 Years | 85 Years | Both | 400 | Phase 3 | United States |
6. パーキンソン病
臨床試験数 : 2,307 / 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00063193 (ClinicalTrials.gov) | May 2003 | 23/6/2003 | National Institute of Neurological Disorders and Stroke (NINDS) Parkinson's Disease Neuroprotection Trial | A Multi-center, Double-blind, Pilot Study of Minocycline and Creatine in Subjects With Early Untreated Parkinson's Disease | Parkinson's Disease | Drug: minocycline;Drug: creatine | University of Rochester | National Institute of Neurological Disorders and Stroke (NINDS) | Completed | 30 Years | N/A | Both | 195 | Phase 2 | United States |
8. ハンチントン病
臨床試験数 : 242 / 薬物数 : 205 - (DrugBank : 62) / 標的遺伝子数 : 85 - 標的パスウェイ数 : 159
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00277355 (ClinicalTrials.gov) | April 2006 | 12/1/2006 | Pilot Study of Minocycline in Huntington's Disease | A Multi-Center, Double-Blind, Pilot Study of Minocycline in Huntington's Disease | Huntington Disease | Drug: minocycline;Drug: Matching placebo | Merit Cudkowicz | FDA Office of Orphan Products Development | Completed | 18 Years | N/A | All | 114 | Phase 2/Phase 3 | United States;Canada |
2 | NCT00029874 (ClinicalTrials.gov) | September 2001 | 24/1/2002 | Minocycline in Patients With Huntington's Disease | Minocycline Dosing and Safety in Huntington's Disease | Huntington's Disease | Drug: Minocycline | FDA Office of Orphan Products Development | NULL | Completed | 18 Years | N/A | Both | 63 | Phase 1/Phase 2 | United States |
13. 多発性硬化症/視神経脊髄炎
臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04291456 (ClinicalTrials.gov) | January 31, 2020 | 18/11/2019 | Minocycline in MS: Confirmation of Benefit | Open-Label Trial of Minocycline in Early Multiple Sclerosis: Confirmation of Treatment Benefit | Multiple Sclerosis;Clinically Isolated Syndrome | Drug: Minocycline 100mg | University of Calgary | Hotchkiss Brain Institute, University of Calgary | Recruiting | 18 Years | 60 Years | All | 148 | Phase 3 | Canada |
2 | NCT01073813 (ClinicalTrials.gov) | February 2010 | 22/2/2010 | Neuroprotection and Repair in Optic Neuritis | Developing Neuroprotection and Repair Strategies in MS: Phase IIa Randomized, Controlled Trial of Minocycline in Acute Optic Neuritis (ON) | Multiple Sclerosis;Optic Neuritis | Drug: Minocycline | University of Calgary | Neuroscience Canada | Terminated | 18 Years | 60 Years | Both | 6 | Phase 2 | Canada |
3 | NCT00666887 (ClinicalTrials.gov) | January 2009 | 23/4/2008 | Minocycline in Clinically Isolated Syndromes (CIS) | A Phase III Double-blind, Randomized, Placebo-controlled Trial of Minocycline in Clinically Isolated Syndromes (CIS) and Early Single Relapse Multiple Sclerosis (MS) | Clinically Isolated Syndromes;Early Single Relapse of Multiple Sclerosis | Drug: Minocycline;Drug: Placebo | Dr. Luanne Metz | Multiple Sclerosis Society of Canada | Completed | 18 Years | 60 Years | All | 142 | Phase 3 | Canada |
4 | NCT01134627 (ClinicalTrials.gov) | February 2006 | 28/5/2010 | Minocycline as add-on to Interferon Beta-1a [IFN Beta-1a] (Rebif®) in Relapsing-Remitting Multiple Sclerosis [RRMS] | A Multi-centre, Double Blind, Randomized, Placebo Controlled, Parallel Group Trial Investigating Minocycline Versus Placebo as Add-on Therapy in Patients Who Are on Treatment With Interferon-beta-1a 44 Mcg Tiw (Rebif®) for the Treatment of Relapsing-Remitting Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting | Drug: Minocycline;Drug: Placebo | Merck KGaA | NULL | Terminated | 18 Years | 55 Years | All | 305 | Phase 2 | Denmark |
5 | EUCTR2005-004289-18-FI (EUCTR) | 26/01/2006 | 07/11/2005 | A Multi-centre, Double Blind, Randomized, Placebo Controlled, Parallel Group Trial Investigating Minocycline versus placebo as add-on therapy in patients who are on treatment with Interferon-beta-1a 44mcg tiw (Rebif®) for the Treatment of Relapsing-Remitting Multiple Sclerosis - Minocycline as add-on to Interferon-beta-1a (Rebif®) in RRMS (Recycline) | A Multi-centre, Double Blind, Randomized, Placebo Controlled, Parallel Group Trial Investigating Minocycline versus placebo as add-on therapy in patients who are on treatment with Interferon-beta-1a 44mcg tiw (Rebif®) for the Treatment of Relapsing-Remitting Multiple Sclerosis - Minocycline as add-on to Interferon-beta-1a (Rebif®) in RRMS (Recycline) | Relapse Remitting Multiple Sclerosis MedDRA version: 8.0;Level: PT;Classification code 10063399 | Product Name: Minocycline 100 mg Film-coated Tablets INN or Proposed INN: Minocycline Hydrochloride | Merck AB | NULL | Not Recruiting | Female: yes Male: yes | 320 | Finland;Sweden | |||
6 | EUCTR2005-004289-18-SE (EUCTR) | 04/01/2006 | 10/11/2005 | A Multi-centre, Double Blind, Randomized, Placebo Controlled, Parallel Group Trial Investigating Minocycline versus placebo as add-on therapy in patients who are on treatment with Interferon-beta-1a 44mcg tiw (Rebif®) for the Treatment of Relapsing-Remitting Multiple Sclerosis - Minocycline as add-on to Interferon-beta-1a (Rebif®) in RRMS (Recycline) | A Multi-centre, Double Blind, Randomized, Placebo Controlled, Parallel Group Trial Investigating Minocycline versus placebo as add-on therapy in patients who are on treatment with Interferon-beta-1a 44mcg tiw (Rebif®) for the Treatment of Relapsing-Remitting Multiple Sclerosis - Minocycline as add-on to Interferon-beta-1a (Rebif®) in RRMS (Recycline) | Relapse Remitting Multiple Sclerosis MedDRA version: 8.0;Level: PT;Classification code 10063399 | Product Name: Minocycline 100 mg Film-coated Tablets INN or Proposed INN: Minocycline Hydrochloride | Merck AB | NULL | Not Recruiting | Female: yes Male: yes | 320 | Finland;Sweden | |||
7 | EUCTR2005-004289-18-DK (EUCTR) | 19/12/2005 | 28/11/2005 | A Multi-centre, Double Blind, Randomized, Placebo Controlled, Parallel Group Trial Investigating Minocycline versus placebo as add-on therapy in patients who are on treatment with Interferon-beta-1a 44mcg tiw (Rebif®) for the Treatment of Relapsing-Remitting Multiple Sclerosis - Minocycline as add-on to Interferon-beta-1a (Rebif®) in RRMS (Recycline) | A Multi-centre, Double Blind, Randomized, Placebo Controlled, Parallel Group Trial Investigating Minocycline versus placebo as add-on therapy in patients who are on treatment with Interferon-beta-1a 44mcg tiw (Rebif®) for the Treatment of Relapsing-Remitting Multiple Sclerosis - Minocycline as add-on to Interferon-beta-1a (Rebif®) in RRMS (Recycline) | Relapse Remitting Multiple Sclerosis MedDRA version: 8.0;Level: PT;Classification code 10063399 | Product Name: Minocycline 100 mg Film-coated Tablets INN or Proposed INN: Minocycline Hydrochloride | E. Merck AB | NULL | Not Recruiting | Female: yes Male: yes | 320 | Finland;Denmark;Sweden | |||
8 | NCT00203112 (ClinicalTrials.gov) | June 2004 | 13/9/2005 | Safety and Efficacy Study of Copaxone Administered in Combination With Minocycline | A Multi-Centered, Randomized, Double-Blind, Placebo-Controlled, Parallel Study Assessing the Add-on Effect of Minocycline in Relapsing-Remitting Multiple Sclerosis (RR-MS) Subjects Treated With Glatiramer Acetate (GA). | Relapse Remitting Multiple Sclerosis | Drug: glatiramer acetate with minocycline;Drug: Glatiramer acetate with placebo | Teva Pharmaceutical Industries | NULL | Completed | 18 Years | 50 Years | Both | 44 | Phase 2 | Canada |
46. 悪性関節リウマチ
臨床試験数 : 4,356 / 薬物数 : 2,567 - (DrugBank : 415) / 標的遺伝子数 : 192 - 標的パスウェイ数 : 228
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT03414502 (ClinicalTrials.gov) | August 2007 | 2/1/2014 | Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response | Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response | Rheumatoid Arthritis | Drug: Methotrexate;Drug: Abatacept;Drug: Adalimumab;Drug: Azathioprine;Drug: Baricitinib;Drug: Certolizumab;Drug: Etanercept;Drug: Golimumab;Drug: Hydroxychloroquine;Drug: Infliximab;Drug: Leflunomide;Drug: Minocycline;Drug: Rituximab;Drug: Sarilumab;Drug: Sulfasalazine;Drug: Tofacitinib | University of Nebraska | NULL | Recruiting | 19 Years | N/A | All | 400 | Phase 3 | United States |
2 | NCT00579644 (ClinicalTrials.gov) | January 2001 | 18/12/2007 | Treatment of Early RA: Minocycline in Combination With Methotrexate vs Methotrexate Alone | Treatment of Early Rheumatoid Arthritis: Minocycline in Combination With Methotrexate Versus Methotrexate Alone | Rheumatoid Arthritis | Drug: Combination of Minocycline and MTX or MTX alone;Drug: methotrexate | University of Nebraska | NULL | Completed | 19 Years | 75 Years | All | 91 | Phase 3 | NULL |
85. 特発性間質性肺炎
臨床試験数 : 627 / 薬物数 : 443 - (DrugBank : 120) / 標的遺伝子数 : 99 - 標的パスウェイ数 : 212
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00203697 (ClinicalTrials.gov) | April 2006 | 13/9/2005 | Minocycline Therapy for Lung Scarring in Patients With Idiopathic Pulmonary Fibrosis - a Pilot Study | Minocycline Treatment in Patients With Idiopathic Pulmonary Fibrosis Being Treated With Standard of Care Therapy- a Pilot Study | Idiopathic Pulmonary Fibrosis | Drug: minocycline | University of California, Los Angeles | NULL | Active, not recruiting | 20 Years | 79 Years | Both | Phase 3 | United States |
90. 網膜色素変性症
臨床試験数 : 147 / 薬物数 : 176 - (DrugBank : 43) / 標的遺伝子数 : 49 - 標的パスウェイ数 : 110
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04068207 (ClinicalTrials.gov) | February 22, 2019 | 23/8/2019 | Minocycline Treatment in Retinitis Pigmentosa | The Efficacy and Safety of Oral Minocycline in the Treatment of Retinitis Pigmentosa: An Open-label Clinical Trial | Retinitis Pigmentosa;Inherited Retinal Dystrophy;Retina Disorder | Drug: Minocycline | Sun Yat-sen University | NULL | Recruiting | 18 Years | 60 Years | All | 35 | Phase 2 | China |
2 | NCT02140164 (ClinicalTrials.gov) | May 2014 | 14/5/2014 | Study of Oral Minocycline in Treating Bilateral Cystoid Macular Edema Associated With Retinitis Pigmentosa | Pilot Study to Evaluate Oral Minocycline in the Treatment of Cystoid Macular Edema Associated With Retinitis Pigmentosa | Retinitis Pigmentosa | Drug: Minocycline | National Eye Institute (NEI) | The EMMES Corporation | Completed | 12 Years | N/A | All | 7 | Phase 1/Phase 2 | United States |
94. 原発性硬化性胆管炎
臨床試験数 : 148 / 薬物数 : 118 - (DrugBank : 39) / 標的遺伝子数 : 18 - 標的パスウェイ数 : 141
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00630942 (ClinicalTrials.gov) | February 2003 | 27/2/2008 | Minocycline in Primary Sclerosing Cholangitis (PSC) | Open Label Pilot Study Evaluating Minocycline in Patients With Primary Sclerosing Cholangitis (PSC) | Primary Sclerosing Cholangitis | Drug: Minocycline | Mayo Clinic | NULL | Completed | 18 Years | 75 Years | Both | 16 | Phase 1 | United States |
162. 類天疱瘡(後天性表皮水疱症を含む。)
臨床試験数 : 90 / 薬物数 : 122 - (DrugBank : 47) / 標的遺伝子数 : 34 - 標的パスウェイ数 : 144
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | ChiCTR-TRC-12003592 | 2011-08-01 | 2012-12-30 | Use of Tripterygium glycosides and Nicotinamide plus Minocycline for the Treatment of bullous pemphigoid: A multicenter,randomized and controlled clinincal trial | Guideline-oriented Research in the Management of Some Common and Severe Skin Diseases | Bullous pemphigoid | Tripterygium glycosides group:Take tripterygium glycosides orally at 20 mg, 3 times a day;Nicotinamide plus Minocycline group:Take nicotinamide at 500 mg, 3 times a day and minocycline 100 mg, twice a day.; | Institute of dermatology, Chinese Academy of Medical Sciences | NULL | Completed | 18 | Both | Tripterygium glycosides group:100;Nicotinamide plus Minocycline group:100; | China |
201. アンジェルマン症候群
臨床試験数 : 25 / 薬物数 : 40 - (DrugBank : 11) / 標的遺伝子数 : 22 - 標的パスウェイ数 : 20
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT02056665 (ClinicalTrials.gov) | January 2014 | 5/2/2014 | Study to Evaluate the Efficacy and Safety of Minocycline in Angelman Syndrome | Randomized Clinical Trial, Placebo Compared to Evaluate the Efficacy and Safety of Minocycline in Angelman Syndrome | Angelman Syndrome | Drug: MINOCYCLINE;Drug: PLACEBO (for Minocycline) | Puerta de Hierro University Hospital | NULL | Completed | 6 Years | 30 Years | Both | 32 | Phase 2 | Spain |
2 | EUCTR2013-002154-67-ES (EUCTR) | 26/12/2013 | 16/09/2013 | STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MINOCYCLINE IN ANGELMAN SYNDROME (A-MANECE STUDY) | RANDOMIZED CLINICAL TRIAL, PLACEBO COMPARED TO EVALUATE THE EFFICACY AND SAFETY OF MINOCYCLINE IN ANGELMAN SYNDROME (A-MANECE STUDY) - A-MANECE | Angelman Syndrome MedDRA version: 16.0;Level: PT;Classification code 10049004;Term: Angelman's syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Aknemin 50 INN or Proposed INN: MINOCYCLINE Other descriptive name: MINOCYCLINE HYDROCHLORIDE | Dra. Cristina Avendaño Solá | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | Spain | ||||
3 | NCT01531582 (ClinicalTrials.gov) | April 2012 | 5/2/2012 | Minocycline in the Treatment of Angelman Syndrome | The Efficacy of Minocycline in the Treatment of Angelman Syndrome | Angelman Syndrome | Drug: minocycline | University of South Florida | NULL | Active, not recruiting | 4 Years | 12 Years | Both | 25 | N/A | United States |
206. 脆弱X症候群
臨床試験数 : 108 / 薬物数 : 91 - (DrugBank : 36) / 標的遺伝子数 : 52 - 標的パスウェイ数 : 77
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT02680379 (ClinicalTrials.gov) | March 2016 | 25/1/2016 | Combined Treatment of Minocycline and Lovastatin to Treat Individuals With Fragile X Syndrome | A Pilot Study Exploring the Safety and Synergistic Effect of a Minocycline/Lovastatin Combined Treatment on the Behavior of Individuals With Fragile X Syndrome; Validation of New Biochemical and Neurophysiological Markers (LovaMiX) | Fragile X Syndrome | Drug: Minocycline, then Minocycline/Lovastatin;Drug: Lovastatin, then Minocycline/Lovastatin | Université de Sherbrooke | FRAXA Research Foundation | Completed | 8 Years | 45 Years | All | 22 | Phase 2 | Canada |
2 | NCT02998151 (ClinicalTrials.gov) | January 2016 | 1/12/2016 | Neurophysiological and Acute Pharmacological Studies in FXS Patients | Neurophysiological and Acute Pharmacological Studies in FXS Patients | Fragile X Syndrome | Drug: Acamprosate;Drug: Lovastatin;Drug: Minocycline;Drug: Placebo;Drug: Baclofen | Children's Hospital Medical Center, Cincinnati | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Completed | 15 Years | 55 Years | All | 29 | Early Phase 1 | United States |
3 | NCT01053156 (ClinicalTrials.gov) | January 2010 | 19/1/2010 | Trial of Minocycline to Treat Children With Fragile X Syndrome | Randomized Double-Blind Controlled Cross Over Trial of Minocycline in Children With Fragile X Syndrome | Fragile X Syndrome | Drug: minocycline hydrochloride;Drug: Placebo | University of California, Davis | The National Fragile X Foundation | Completed | 42 Months | 16 Years | All | 66 | N/A | United States |
4 | NCT00858689 (ClinicalTrials.gov) | October 2007 | 9/3/2009 | Add-on Pilot Trial of Minocycline to Treat Fragile X Syndrome | Add-on Pilot Trial of Minocycline in Fragile X Syndrome | Fragile X Syndrome | Drug: Minocycline | FRAXA Research Foundation | Fragile X Research Foundation of Canada | Completed | 13 Years | 35 Years | All | 20 | N/A | Canada |
280. 巨大動静脈奇形(頚部顔面又は四肢病変)
臨床試験数 : 27 / 薬物数 : 30 - (DrugBank : 15) / 標的遺伝子数 : 14 - 標的パスウェイ数 : 153
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00243893 (ClinicalTrials.gov) | July 2004 | 24/10/2005 | Tetracycline-Derivatives for Treatment of Cerebral Arteriovenous Malformations and Aneurysms | Tetracycline-Derivatives for Treatment of Cerebral Arteriovenous Malformations and Aneurysms | Aneurysms;Arteriovenous Malformations | Drug: minocycline;Drug: doxycycline | University of California, San Francisco | National Institute of Neurological Disorders and Stroke (NINDS) | Completed | 13 Years | 80 Years | Both | 26 | Phase 1 | United States |
299. 嚢胞性線維症
臨床試験数 : 1,695 / 薬物数 : 1,527 - (DrugBank : 268) / 標的遺伝子数 : 111 - 標的パスウェイ数 : 174
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT03489629 (ClinicalTrials.gov) | April 3, 2018 | 29/3/2018 | STaph Aureus Resistance-Treat Early and Repeat (STAR-TER) | STaph Aureus Resistance-Treat Early and Repeat (STAR-TER) | Cystic Fibrosis | Drug: Trimethoprim Sulfamethoxazole (TMP/SMX);Drug: Minocycline;Drug: Mupirocin;Drug: Chlorhexidine Gluconate;Behavioral: Environmental Decontamination | University of North Carolina, Chapel Hill | University of Washington;Cook Children's Medical Center;Indiana University;University of Michigan;University of Texas Southwestern Medical Center;St. Louis Children's Hospital | Recruiting | 2 Years | 45 Years | All | 42 | Phase 2 | United States |
2 | EUCTR2013-000219-25-IT (EUCTR) | 18/07/2013 | 12/04/2018 | MRSA study. | Early eradication of S. Aureus (MRSA) in patients with cystic fibrosis: a randomized multicenter study. | Patients affected by cystic fibrosis and who present an initial infection of MRSA.;Therapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01] | Product Name: Rifampin INN or Proposed INN: RIFAMPICIN Product Name: Trimethoprim-sulfamethoxazole INN or Proposed INN: SULFAMETHOXAZOLE Other descriptive name: TRIMETHOPRIM Product Name: minocycline Other descriptive name: MINOCYCLINE HYDROCHLORIDE | AOU Meyer | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 100 | Phase 3 | Italy | ||
3 | NCT01349192 (ClinicalTrials.gov) | April 2011 | 4/5/2011 | Early Methicillin-resistant Staphylococcus Aureus (MRSA) Therapy in Cystic Fibrosis (CF) | Early MRSA Therapy in CF - Culture Based vs. Observant Therapy (Treat or Observe) (Star-TOO - STaph Aureus Resistance - Treat or Observe) | Cystic Fibrosis;Methicillin-resistant Staphylococcus Aureus | Drug: Rifampin;Drug: Trimethoprim/Sulfamethoxazole;Drug: Minocycline;Drug: Mupirocin;Drug: chlorhexidine gluconate oral rinse;Drug: 2% Chlorhexidine solution wipes;Behavioral: Environmental Decontamination | University of North Carolina, Chapel Hill | CF Therapeutics Development Network Coordinating Center;Seattle Children's Hospital;Washington University School of Medicine;University of Washington;University of Colorado, Denver;Baylor College of Medicine;University of Alabama at Birmingham;Cook Children's Medical Center;University of Michigan;University of Florida;University of Texas Southwestern Medical Center;Children's Hospital Medical Center, Cincinnati;St. Louis Children's Hospital | Terminated | 4 Years | 45 Years | All | 47 | Phase 2 | United States |